Clinical Trials Sponsored by Vyriad, Inc.

Total 35506 results

Vyriad, Inc.

Terminated

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Recurrent Non-Small Cell Lung Cancer

United States
Vyriad, Inc.

Completed

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Malignant Solid Tumour

United States
Vyriad, Inc.
Mayo Clinic

Completed

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

Urothelial Carcinoma

United States
Vyriad, Inc.
Regeneron Pharmaceuticals

Recruiting

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Melanoma | Head and Neck Squamous Cell Carcinoma | Colo-rectal Cancer

United States, Brazil
Vyriad, Inc.
Mayo Clinic

Recruiting

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Solid Tumor | Non Small Cell Lung Cancer | Neuroendocrine Carcinoma

United States
Myriad Genetic Laboratories, Inc.
Myriad Genetics, Inc.

Completed

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

Hereditary Cancer

United States
Myriad Therapeutics, Inc.

Terminated

Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

Cancer

United States
UNICANCER
Myriad Genetics, Inc.

Completed

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer (ADENDOM)

Breast Cancer
Myriad Genetic Laboratories, Inc.

Terminated

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Prostate Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

EndoPredict® Extended Endocrine Trial (EXET)

Primary Invasive Breast Cancer

United States
Myriad Genetic Laboratories, Inc.

Completed

Combined Breast Cancer Risk Study

Hereditary Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (ONC003)

NSCLC | Lung Cancer | Lung Adenocarcinoma

United States
Myriad Genetic Laboratories, Inc.

Completed

Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

Prostate Cancer

United States
Myriad Genetic Laboratories, Inc.

Recruiting

Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing

Prostate Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (PROFUSE)

Colorectal Cancer, Metastatic

United States
BeiGene
Myriad Genetics, Inc.

Completed

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Spain, Australia, United States, United Kingdom
Myriad Genetic Laboratories, Inc.

Completed

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing (URO-009Low)

Prostate Cancer

United States
Myriad Genetic Laboratories, Inc.

Terminated

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (ONC006)

NSCLC | Lung Cancer | NSCLC Adenocarcinoma

United States
Myriad Genetic Laboratories, Inc.

Withdrawn

Endometriosis Biomarker Discovery Study (EMBARK)

Endometriosis | Chronic Pelvic Pain
Myriad Genetic Laboratories, Inc.

Completed

Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients (PROCEDE-2000)

Prostate Cancer

United States
General Oncology, Inc.
Myriad Genetics, Inc.

Recruiting

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditions

United States
AstraZeneca
Myriad Genetic Laboratories, Inc.

Withdrawn

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Platinum Sensitive Relapsed Ovarian Cancer

United States, Korea, Republic of, Peru, United Kingdom, Philippines
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Terminated

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

United States, Spain, United Kingdom, Germany, France
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Withdrawn

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Ovarian Cancer
Myriad Genetic Laboratories, Inc.
Intermountain Health Care, Inc.

Terminated

Registry to Measure the Impact of Adding Genomic Testing

Prostate Cancer

United States
University of Pennsylvania
AstraZeneca; Myriad Genetics, Inc.

Recruiting

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)

High Grade Serous Carcinoma

United States
Myriad Genetic Laboratories, Inc.
University of Minnesota

Completed

Bipolar Proteomic Assay Validation Study

Major Depressive Disorder, Bipolar I and Bipolar II

United States
Dana-Farber Cancer Institute
Myriad Genetics, Inc.

Active, not recruiting

Genetic Testing for All Breast Cancer Patients (GET FACTS)

Breast Cancer | Invasive Breast Cancer | Genetic Testing | in Situ Breast Cancer

United States
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Spain, Canada, Australia, United Kingdom, France
M.D. Anderson Cancer Center
Myriad Genetic Laboratories, Inc.

Withdrawn

Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Breast Cancer
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
Myriad Genetic Laboratories, Inc.
Carolina Urologic Research Center

Completed

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Prostate Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Metastatic Castration-resistant Prostate Cancer

China
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Metastatic Castration-resistant Prostate Cancer

United States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
Stanford University
Varian Medical Systems, Inc.

Recruiting

Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

Metastatic Adenocarcinoma of the Pancreas | Germline BRCA1/2 Mutations and

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Germany, Korea, Republic of, Australia, Israel, Netherlands
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)

Recurrent Platinum Resistant Ovarian Cancer

United States
AstraZeneca
Parexel; Covance; Iqvia Pty Ltd; Theradex; Myriad Genetics, Inc.

Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)

Non-Germline BRCA Mutated Ovarian Cancer

Italy, Spain, Sweden, Canada, Czechia, Poland, United Kingdom, Israel, Austria, Belgium, Switzerland, Netherlands, Bulgaria, Finland, Norway, Denmark, Slovenia, Portugal
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
Myriad Genetic Laboratories, Inc.
VA Salt Lake City Health Care System

Terminated

Prospective Prolaris Value and Efficacy (P-PROVE)

Prostate Cancer

United States
Damascus University
St Joseph University, Beirut, Lebanon; Syrian Atomic Energy Agency, Damascus...

Completed

Clinical Efficacy of the Immediate Implant Loading

Implant Site Reaction

Lebanon, Syrian Arab Republic
Varian Medical Systems

Completed

STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma

Localized Hepatocellular Carcinoma

China
Dana-Farber Cancer Institute
Translational Breast Cancer Research Consortium; Myriad Genetics, Inc.

Completed

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Syrian Private University

Completed

Awareness About Rheumatic Diseases in a Sample of Syrian Population

Rheumatic Diseases

Syrian Arab Republic
Syrian Private University

Completed

Diabetes Complications and Hearing Loss

Diabetes Mellitus | Diabetes Complications | Hearing Loss

Syrian Arab Republic
Lahey Clinic
Varian Medical Systems; Merit Medical Systems, Inc.

Active, not recruiting

Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant (SBRTvsTACE)

HCC | Hepatocellular Carcinoma

United States, Canada

Clinical Trials Sponsored by Vyriad, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations